Clinical trial

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

NCT03653546

Study summary

ClinicalTrials.gov

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention AZD3759 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Erlotinib Normalized identity: erlotinib View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Gefitinib Normalized identity: gefitinib View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-10-29

PhasePHASE2 / PHASE3

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

EGFR Gene Mutationunresolved

Brain Metastasesunresolved

Interventions

AZD3759DRUG

ErlotinibDRUG · verified · RxNorm: erlotinib

GefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

Alpha Biopharma (Jiangsu) Co., Ltd.lead sponsor

Mapped research locations

SeoulSouth Korea5 BeijingChina4 HangzhouZhejiang, China3 WuhanHubei, China3 GuangzhouGuangdong, China2 ShanghaiChina2 NanjingJiangsu, China2 ZhengzhouHenan, China2 ChangchunJilin, China2 ChongqingChina2 TaipeiTaiwan1 TaichungTaiwan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03653546 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.